Importantly, the ability of K7174 to sensitize prostate cancer cells to enzalutamide treatment indicates that future studies should consider combining GATA2 inhibitors and enzalutamide to improve the therapeutic efficacy of enzalutamide in the treatment of prostate cancer. Here, GATA2 is linked to prostate carcinoma.